第一条 为充分发挥独立董事在董事会中参与决策、监督制衡、专业咨询等 职能，进一步规范浙江佐力药业股份有限公司（以下简称"公司"）的法人治理 结构，保护中小股东及利益相关者的利益，促进公司的规范运作，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《上市公司 独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《浙江佐力药 业股份有限公司章程》（以下简称《公司章程》）、《浙江佐力药业股份有限公 司独立董事制度》的有关规定，特制定本制度。 第二条 独立董事专门会议是指公司应当召开全部由独立董事参加的会议， 为履行独立董事职责专门召开的会议。独立董事专门会议对所议事项进行独立研 讨，应当从合法合规性、可能存在的风险以及对公司和中小股东权益的影响进行 思考判断，并且形成讨论意见。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）的规定、证券 交易所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与决 策、监督制衡、专业咨询作用 ...

Core Viewpoint - The document outlines the work system for independent directors and the audit committee of Zhejiang Zhaoli Pharmaceutical Co., Ltd., emphasizing the importance of governance structure and internal control in the preparation and disclosure of annual reports [1][2]. Summary by Sections Governance Structure - The company aims to enhance its governance structure and internal control by establishing a work system for independent directors and the audit committee [1][2]. Responsibilities of Independent Directors and Audit Committee - Independent directors and the audit committee are required to diligently perform their duties to ensure the annual report is true, accurate, complete, and timely, thereby safeguarding the overall interests of the company [2][3]. - The management must report the company's operational status and significant investment and financing activities to independent directors within 30 days after the end of each fiscal year [3]. Audit Process - The audit committee is responsible for evaluating the qualifications of the accounting firm to be hired and must coordinate with the financial supervisor and the accounting firm regarding the timing of the annual financial report audit [4][5]. - Prior to the audit, independent directors and the audit committee must communicate with the auditors regarding the audit plan, team composition, risk assessment, and key audit areas [5][6]. Communication and Reporting - The audit committee must ensure that the accounting firm submits the audit report within the agreed timeframe and maintain written records of the communication process [6]. - After the auditors provide preliminary opinions, a meeting must be arranged between independent directors, the audit committee, and the auditors to discuss any issues found during the audit [6][7]. Review and Approval - Independent directors must review the board meeting procedures and necessary documents before the board discusses the annual report, and they can refuse to attend if there are deficiencies [7][8]. - The audit committee must vote on the audited financial report and submit their opinions to the board, including a summary report from the accounting firm [8][9]. Confidentiality and Compliance - Independent directors and audit committee members are obligated to maintain confidentiality and prevent insider trading or information leaks prior to the disclosure of the annual report [9][10]. - The document stipulates that any communication or suggestions related to the annual report must be recorded in writing and stored by the company [10][11]. Implementation - The work system will be effective upon approval by the board and will be interpreted by the board of directors [11][12].

Core Viewpoint - The document outlines the management system for shareholding and trading of shares by directors and senior management of Zhejiang Zoli Pharmaceutical Co., Ltd, emphasizing compliance with relevant laws and regulations to prevent insider trading and ensure transparency in share transactions [1][2]. Group 1: General Principles - The system applies to directors, senior management, and other specified individuals or organizations regarding their holding and trading of the company's shares [1]. - Senior management includes positions such as the general manager, executive vice president, vice presidents, board secretary, and financial director [2]. Group 2: Share Trading Declaration - Directors and senior management must notify the board secretary in writing of their trading plans before executing any trades, allowing for verification against legal and regulatory compliance [5]. - The company must apply to the stock exchange and the China Securities Depository and Clearing Corporation for the registration of shares held by directors and senior management under certain conditions, such as share issuance or equity incentive plans [6]. Group 3: Trading Restrictions - Directors and senior management are prohibited from engaging in margin trading of the company's shares if they hold more than 5% of the shares [11]. - During their term and for six months after, directors and senior management can only transfer up to 25% of their shares through various methods, with exceptions for certain circumstances [12]. Group 4: Insider Trading Prohibitions - Directors and senior management cannot trade shares during specific periods, such as 15 days before annual or semi-annual reports and 5 days before quarterly reports [18]. - They must ensure that close relatives and controlled entities do not trade based on insider information [20]. Group 5: Disclosure of Shareholding Changes - The board secretary is responsible for managing and reporting the shareholding data of directors and senior management, ensuring compliance with disclosure requirements [21]. - Any increase in shareholding must be disclosed, including details about the number of shares, purpose, and implementation timeline [22]. Group 6: Penalties for Violations - Any profits gained from violations of the trading rules must be returned to the company, and severe cases may lead to disciplinary actions against the responsible individuals [27].

Core Viewpoint - The document outlines the work system for the Secretary of the Board of Directors of Zhejiang Zhaoli Pharmaceutical Co., Ltd., emphasizing the need for compliance with laws and regulations, as well as the responsibilities and qualifications required for the position. Group 1: General Provisions - The work system is established to regulate the behavior of the Secretary of the Board, ensuring the company's compliance and protection of investors' rights [1] - The Secretary of the Board is a senior management position responsible to the company and the Board [1] Group 2: Qualifications and Appointment Procedures - The Board appoints or dismisses the Secretary, who serves a term of three years, with the possibility of reappointment [4] - Candidates must meet legal and regulatory requirements, possess relevant professional knowledge, and demonstrate good ethical standards [2][4] Group 3: Dismissal and Reporting - The company must have valid reasons for dismissing the Secretary, and any dismissal must be reported to the stock exchange [3] - The Secretary must be dismissed if they cannot perform their duties for over three months or if they violate the established work system [3][4] Group 4: Responsibilities - The Secretary is responsible for managing information disclosure, ensuring compliance with disclosure regulations, and maintaining confidentiality [12] - The Secretary assists in strengthening corporate governance, organizing meetings, and ensuring compliance with securities laws [13][14] Group 5: Support and Resources - The company must provide necessary conditions for the Secretary to perform their duties, including access to financial and operational information [17] - The Board should appoint a securities affairs representative to assist the Secretary when needed [20]

浙江佐力药业股份有限公司 子公司管理制度 第一章 总则 第一条 为了进一步规范浙江佐力药业股份有限公司（以下简称"母公司"） 及其子公司的组织行为，确保子公司规范、高效、有序地运作，促进子公司健康 发展，提高公司整体资产运营质量，维护公司和各投资人的合法权益，根据《中 华人民共和国公司法》 （以下简称"《公司法》"）等法律、法规、规章、规范性文 件及《公司章程》的有关规定，结合经营发展的实际需要，特制定本制度。 第二条 本制度所称子公司是指纳入公司合并报表范围内的、被公司控股或 实际控制的被投资公司。 第三条 公司主要通过委派董事、监事、高级管理人员和日常监管两种方式 对子公司进行管理。 第四条 加强对子公司的管理，旨在建立有效的控制机制，对公司的组织、 资源、资产、投资等和公司的运作进行风险控制，提高公司整体运作效率和抗风 险能力。 第七条 公司派出人员在子公司的职责： （一）依法行使相关权利，承担相关管理责任； （二）督促子公司认真遵守国家有关法律、法规的规定，依法经营，规范运 作； （三）协调公司与子公司之间的有关工作； （四）保证公司发展战略、董事会及股东会决议的贯彻执行； （五）忠实、勤勉、尽职尽责 ...

Core Points - The article outlines the management system for the resignation of directors and senior management at Zhejiang Zoli Pharmaceutical Co., Ltd, aiming to ensure stable corporate governance and protect shareholders' rights [1][2][4] Group 1: General Provisions - The system is established based on relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1] - It applies to directors (including independent directors) and senior management who leave due to various reasons such as term expiration, resignation, retirement, or dismissal [1][2] Group 2: Resignation Conditions and Effectiveness - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the board, with disclosure required within two trading days [2] - If a director's term expires without re-election, they automatically leave office from the date the shareholders' meeting resolution is passed [2] Group 3: Restrictions on Holding Office - Certain individuals are prohibited from serving as directors or senior management, including those with limited civil capacity, criminal convictions related to corruption, or those who have been declared unfit by regulatory bodies [2][4] Group 4: Transition Procedures and Unresolved Matters - Resigning directors and senior management must hand over all relevant documents and assets within five working days after their resignation becomes effective [4][5] - If significant matters such as major investments or financial decisions are involved, an audit committee may initiate a departure audit [5] Group 5: Obligations of Resigning Directors and Senior Management - Resigning individuals must fulfill all handover procedures and maintain their obligations of loyalty and confidentiality for two years post-termination [5][6] - They are restricted from transferring more than 25% of their shares annually during their term and cannot transfer shares within six months after leaving [6] Group 6: Accountability Mechanism - The board may take necessary actions to hold resigning directors and senior management accountable for any violations of commitments or actions that harm the company [6][7] - Individuals can appeal the board's accountability decisions within fifteen days of notification [7]

浙江佐力药业股份有限公司 投资者关系管理制度 第一章 总则 第一条 为了加强浙江佐力药业股份有限公司（以下简称"公司"）与投资者 和潜在投资者（以下合称"投资者"）之间的信息沟通，切实建立公司与投资者 （特别是社会公众投资者）的良好沟通平台，完善公司治理结构，切实保护投资 者（特别是社会公众投资者）的合法权益，形成公司与投资者之间长期、稳定、 和谐的良性互动关系，特制定本制度以供有关各方遵守。 第二条 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》 （以下简称"《证券法》"）、 《深圳证券交易所创业板股票上市规 则》 （以下简称" 《上市规则》"） 、《上市公司投资者关系管理工作指引》以及《浙 江佐力药业股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，特制定 本制度。 第三条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第四条 公司开展投资者关系管理工作应体现公平、公 ...

Core Points - The internal audit system of Zhejiang Zoli Pharmaceutical Co., Ltd. aims to standardize internal audit work, improve quality, and protect investors' rights [2] - The internal audit applies to all business activities related to corporate governance, financial reporting, and information disclosure across the company and its subsidiaries [2] - The board of directors is responsible for establishing and implementing the internal control system, ensuring the accuracy and completeness of related disclosures [3] Group 1 - The internal audit is defined as an evaluation activity conducted by internal personnel to assess the effectiveness of internal controls, risk management, and the authenticity of financial information [2] - The internal control process aims to ensure compliance with laws, improve operational efficiency, safeguard assets, and ensure fair and accurate information disclosure [2] - The audit committee, composed of independent directors, oversees the internal audit department and ensures its independence from the finance department [4][5] Group 2 - The internal audit department is required to have at least three dedicated personnel who possess necessary knowledge, adhere to ethical standards, and maintain independence [8] - The internal audit department must report to the audit committee and submit an annual audit work plan and report [7][8] - The internal audit should cover all business activities related to financial reporting and information disclosure, including sales, procurement, asset management, and human resources [19][20] Group 3 - The internal audit department is responsible for evaluating the integrity and effectiveness of internal controls, auditing financial data, and assisting in fraud prevention [15][16] - The audit committee must review the internal audit reports and ensure that any identified deficiencies are addressed promptly [10][13] - The internal audit department must conduct audits of significant transactions, including investments, asset purchases, and related party transactions, ensuring compliance with approval procedures [10][11][12]

第二条 本制度所称累积投票是指股东会选举董事时，股东所持每一有表决 权股份拥有与应选出董事人数相等的投票表决权，股东拥有的投票表决权总数等 于其所持有的有表决权股份与应选董事人数的乘积。股东可以按意愿将其拥有的 全部投票表决权集中投向某一位或几位董事候选人，也可以将其拥有的全部投票 表决权进行分配，分别投向各位董事候选人的一种投票制度。 浙江佐力药业股份有限公司 累积投票管理制度 第一章 总则 第一条 为进一步完善浙江佐力药业股份有限公司（以下简称"公司"）法人 治理结构，规范公司董事的选举，保证所有股东充分行使权利，维护中小股东利 益，根据《上市公司治理准则》 《深圳证券交易所创业板股票上市规则》 《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《浙江佐 力药业股份有限公司章程》 （以下简称"《公司章程》"）及其他有关规定，并结合 公司实际情况制定本制度。 第三条 本制度所称的"董事"包括独立董事和非独立董事，特指非由职工 代表担任的董事。由职工代表担任的董事由公司职工代表大会选举产生或更换， 不适用本管理制度的相关规定。 第四条 股东会选举产生的董事人数及结构应符合《公司章程》 ...

浙江佐力药业股份有限公司 总经理工作细则 第一章 总则 第一条 为进一步提高浙江佐力药业股份有限公司（以下称"公司"）总经理 及其他高级管理人员的管理水平和管理效率，规范议事方式和决策程序，保障总 经理及其他高级管理人员合法有效地履行其职责，根据《中华人民共和国公司法》 《中华人民共和国证券法》及其他法律法规和《浙江佐力药业股份有限公司章程》 （以下称"《公司章程》"）的规定，结合公司的实际情况制定本工作细则。 第二条 总经理主持公司日常经营和管理工作，组织实施董事会决议，对董 事会负责。 第二章 总经理的任职资格和任免程序 第三条 公司设总经理一名，由董事会聘任或解聘。 第四条 具有下列情形之一的人员，不得担任公司总经理： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾五年，被宣告缓刑的， 自缓刑考验期满之日起未逾二年； （三）担任破产清算的公司、企业的董事或者厂长、经理，对该公司、企业 的破产负有个人责任的，自该公司、企业破产清算完结之日起未逾三年； （四）担任因违法被吊销营业执照、责令关 ...